This medtech name on Josh Brown's list is hitting the sweet spot for momentum

Edwards Lifesciences raised full-year 2026 guidance to 9%–11% constant-currency sales growth, implying revenue of $6.5B–$6.9B, with adjusted EPS guided to $2.95–$3.05 and operating margin at the high end of 28%–29% (about 150bps expansion). Its newest heart-related therapies segment grew roughly 42% year over year in Q1 2026, and management reiterated a long-term target of about 10% average annual sales growth plus 50–100bps of annual margin expansion. Technically, EW broke out above an $87 resistance level after building a $75–$87 base, with $81 now cited as the key stop/support zone.

Analysis

EW looks like a rare overlap of three vectors that usually do not arrive together: accelerating end-market relevance, improving margin structure, and a chart that has already forced incremental capital back in. The important second-order effect is that success in structural heart tends to expand the addressable market by shifting treatment earlier in the disease curve, which can sustain growth even if procedure volumes normalize from current enthusiasm. That makes this less of a one-quarter earnings story and more of a multi-year re-rating candidate if the company can keep converting clinical adoption into durable pricing power.

The competitive read is favorable for EW because category leaders in medtech often win on procedural standardization, training, and physician habit formation rather than on raw product differentiation alone. Once a stock clears a long base and reclaims the old ceiling, sellers tend to be depleted; if fundamentals are simultaneously inflecting, the next leg can be driven by both systematic momentum and fundamental underownership. The implication for peers is that capital may rotate toward the cleaner growth compounder in structural heart, pressuring slower-growth diversified device names to justify their multiples with better capital returns or M&A.

Risk is less about a near-term miss and more about whether growth decelerates after the easy comparisons roll off over the next 2-3 quarters. The market is already rewarding the breakout, so any guide-down in the fastest-growing segment or evidence that margin expansion is peaking would likely trigger a fast de-rating back into the prior base. A close back below the reclaimed support zone would matter because it would signal the breakout was more a short-covering event than a true institutional accumulation phase.

Key Decisions for Investors

• Add to EW on any pullback toward the former breakout/support zone over the next 1-4 weeks; risk/reward is attractive as long as the stock holds the retest low, with a failed support break implying a quick exit rather than a trend hold.
• For momentum portfolios, hold EW as a 3-6 month core long while the 50/200-day compression resolves upward; use a close below support as the hard stop, not an arbitrary percentage stop.
• Pair trade: long EW / short a slower-growth medtech or diversified device basket over the next 2-3 quarters to express relative growth-quality rotation; this isolates the structural heart re-rating rather than broad healthcare beta.
• Consider a call spread in EW with 3-6 month tenor if implied volatility remains manageable; the thesis is continuation off a multi-month base, so capped-risk upside exposure is better than outright stock if you want defined downside.
• Avoid chasing if the stock gaps sharply on no new fundamental data; the better entry is either a successful retest or a narrow consolidation above the breakout, because that would signal genuine institutional sponsorship rather than headline-driven flow.